Stock Market News
4d Pharma submits new IBS drug application to FDA
AIM-quoted pharmaceutical company 4d Pharma has submitted an investigational new drug application for Blautix, its live biotherapeutic for the treatment of irritable bowel syndrome, to the US Food and Drug Administration.
4d has consulted with the FDA on the design of the study, which will see up to 500 patients receive either Blautix or a placebo on a daily basis for eight weeks, the primary endpoint of which will be to see an improvement in abdominal pain and stool frequency or consistency for at least four of those weeks.
The double-blind, placebo-controlled multicentre Phase II study will evaluate the efficacy and safety of Blautix in patients with IBS, in the form of constipation and diarrhoea.
A range of secondary efficacy endpoints will also be assessed, as well as the effects of Blautix on the gut microbiome.
Dr Alex Stevenson, 4d's chief scientific officer, said, "We are delighted to advance Blautix into this important proof-of-concept study, which brings us another step closer to bringing a novel treatment regime to patients."
"IBS is poorly addressed with current therapies, which only target the symptoms of the disease rather than tackling the underlying causes. By targeting the microbiome, Blautix has the potential to make a real difference for patients and could represent a new era in the treatment of IBS," Stevenson added.
Enrolment in the Phase II study was expected to begin during the second half of 2018.
As of 0900 BST, 4d shares had grown 4.25% to 135.00p.
4d has consulted with the FDA on the design of the study, which will see up to 500 patients receive either Blautix or a placebo on a daily basis for eight weeks, the primary endpoint of which will be to see an improvement in abdominal pain and stool frequency or consistency for at least four of those weeks.
The double-blind, placebo-controlled multicentre Phase II study will evaluate the efficacy and safety of Blautix in patients with IBS, in the form of constipation and diarrhoea.
A range of secondary efficacy endpoints will also be assessed, as well as the effects of Blautix on the gut microbiome.
Dr Alex Stevenson, 4d's chief scientific officer, said, "We are delighted to advance Blautix into this important proof-of-concept study, which brings us another step closer to bringing a novel treatment regime to patients."
"IBS is poorly addressed with current therapies, which only target the symptoms of the disease rather than tackling the underlying causes. By targeting the microbiome, Blautix has the potential to make a real difference for patients and could represent a new era in the treatment of IBS," Stevenson added.
Enrolment in the Phase II study was expected to begin during the second half of 2018.
As of 0900 BST, 4d shares had grown 4.25% to 135.00p.
Related share prices |
---|
4D Pharma (DDDD) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price